Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Rapid adoption of CASGEVY and successful Phase 3 outcomes in pain management diversify revenue streams and reaccelerate top-line growth, driving multiple expansion.
CASGEVY Launch Stalls: Severe underperformance in commercial scaling of CASGEVY due to treatment center bottlenecks or reimbursement pushback, impairing growth.
Vertex is a highly profitable, mature compounder with a dominant franchise in cystic fibrosis generating massive free cash flow. The next phase of growth relies on successfully commercializing its pipeline, including CASGEVY for sickle cell disease and novel pain treatments.
Vertex is a highly profitable, mature compounder with a dominant franchise in cystic fibrosis generating massive free cash flow. The next phase of growth relies on successfully commercializing its pipeline, including CASGEVY for sickle cell disease and novel pain treatments.
Cystic fibrosis therapeutics monopoly with high switching costs and IP protection
Specialized distribution and manufacturing scale
Biotech expansion phase driven by favorable FDA approvals, loose capital access, and premium valuations assigned to de-risked late-stage assets.
Strong Buy. Robust 33.65% upside to $574.46 fair value, supported by extended duration of the CF monopoly and massive free cash flow generation, adequately mitigating pipeline execution risks.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
A 5x5 sensitivity grid highlights that if operating margins compress below historical norms or terminal growth decelerates below 2.0%, fair value approaches the $428.44 floor. Base FCFF remains positive under stress without a capital cliff, provided R&D leverage holds.
Cystic fibrosis therapeutics monopoly with high switching costs and IP protection
Specialized distribution and manufacturing scale
Proven R&D engine in targeted genetic therapies
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $3.7B after capex $432.0M, with terminal value at 71.3% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If CF revenues beat and CASGEVY patient starts exceed estimates -> Multiple expansion. If pain pipeline data underwhelms -> Multiple compression toward biotech sector average.
If CF revenues beat and CASGEVY patient starts exceed estimates -> Multiple expansion. If pain pipeline data underwhelms -> Multiple compression toward biotech sector average.
If CF revenues beat and CASGEVY patient starts exceed estimates -> Multiple expansion. If pain pipeline data underwhelms -> toward biotech sector average.
Internally funded through massive FCF ($3.6B OCF in 2025), enabling aggressive pipeline investments and share repurchases without external dilution.
Biotech expansion phase driven by favorable FDA approvals, loose capital access, and premium valuations assigned to de-risked late-stage assets.
Regulatory tightening, drug pricing legislation (IRA pressure), and constrained healthcare budgets depressing terminal multiples across the sector.
Internally funded through massive FCF ($3.6B OCF in 2025), enabling aggressive pipeline investments and share repurchases without external dilution.
Core holding sizing appropriate for a mature quality compounder, scaled to conviction around pipeline delivery.
Trim exposure if intrinsic models hit the upper bound ($721.50) or if key non-CF pipeline assets suffer terminal clinical failures.
Strong Buy. Vertex offers highly visible base cash flows from its CF monopoly combined with compelling optionality from its non-opioid pain and gene-editing pipelines.
The synthesized fair value tightly integrates robust DCF and moat-duration evidence. Structural divergence from flawed PEG models is explicitly justified.
Strong Buy. Vertex offers highly visible base cash flows from its CF monopoly combined with compelling optionality from its non-opioid pain and gene-editing pipelines.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Clinical trial setbacks in non-CF pipeline assets or slower-than-expected commercial uptake leave the company overly reliant on a maturing cystic fibrosis market, leading to multiple compression.
Severe underperformance in commercial scaling of CASGEVY due to treatment center bottlenecks or reimbursement pushback, impairing growth.
Phase 3 failures or regulatory rejection of the non-opioid pain pipeline (JOURNAVX), eliminating a key diversification pillar.
Unexpected success of a rival one-time gene-editing therapy functionally curing CF, prematurely collapsing the core TRIKAFTA revenue stream.
The five developments that would weaken our investment case.
A sharp slowdown in cystic fibrosis franchise revenue growth would indicate patient market saturation or emerging therapeutic competition, threatening the core commercial cash generator supporting diversified pipeline investments.
Current:8.9% for the period ended 2025-12-31
Alert ifDecelerates below 5.0% over any trailing twelve-month period
Inability to secure timely European reimbursement agreements restricts commercial adoption for novel gene therapies, failing to validate non-CF diversification assumptions and slowing high-margin revenue growth needed to expand beyond the core franchise.
Current:Commercial scaling active as of 2026-05-10
Alert ifFiled reimbursement rejection or formal pricing suspension in >= 2 major European markets within a 12-month window
Unproductive research expenditures and pipeline development setbacks erode capital efficiency, destroying economic value if late-stage programs fail to deliver high-margin commercial blockbusters.
Current:17.8% as of 2026-05-10
Alert ifDeclines below 12.0% as of any annual measurement date
Failure to maintain operational leverage amid heavier manufacturing and clinical expenses compresses cash generation, reducing funds available for capital returns and strategic pipeline expansion.
Current:37.9% for the period ended 2025-12-31
Alert ifDrops below 32.0% over any trailing twelve-month period
A persistent decline in cash conversion efficiency relative to net earnings indicates worsening working capital drag or inventory build-up for newly launched commercial therapies, constraining operational liquidity.
Current:0.919 as of 2026-05-10
Alert ifDeclines below 0.750 as of any quarterly analysis date
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Rapid adoption of CASGEVY and successful Phase 3 outcomes in pain management diversify revenue streams and reaccelerate top-line growth, driving multiple expansion.
Vertex maintains its CF monopoly while steadily scaling CASGEVY and securing approval for its pain portfolio. Margins hold flat at 38% and revenue fades to 5% mid-term.
If CF revenues beat and CASGEVY patient starts exceed estimates -> Multiple expansion. If pain pipeline data underwhelms -> Multiple compression toward biotech sector average.
Warning level: Decelerates below 5.0% over any trailing twelve-month period. A sharp slowdown in cystic fibrosis franchise revenue growth would indicate patient market saturation or emerging therapeutic competition, threatening the core commercial cash generator supporting diversified pipeline investments.
Warning level: Filed reimbursement rejection or formal pricing suspension in >= 2 major European markets within a 12-month window. Inability to secure timely European reimbursement agreements restricts commercial adoption for novel gene therapies, failing to validate non-CF diversification assumptions and slowing high-margin revenue growth needed to expand beyond the core franchise.
Warning level: Declines below 12.0% as of any annual measurement date. Unproductive research expenditures and pipeline development setbacks erode capital efficiency, destroying economic value if late-stage programs fail to deliver high-margin commercial blockbusters.
Warning level: Drops below 32.0% over any trailing twelve-month period. Failure to maintain operational leverage amid heavier manufacturing and clinical expenses compresses cash generation, reducing funds available for capital returns and strategic pipeline expansion.
Warning level: Declines below 0.750 as of any quarterly analysis date. A persistent decline in cash conversion efficiency relative to net earnings indicates worsening working capital drag or inventory build-up for newly launched commercial therapies, constraining operational liquidity.
| $9.87B |
| $11.02B |
| $12.00B |
| +10.4% |
| Gross profit | $7.85B | $8.61B | $9.49B | $10.35B | +9.7% |
| Operating income | $4.29B | $4.42B | $279.1M | $4.66B | +2.8% |
| Net income | $3.32B | $3.62B | $-535.6M | $3.95B | +6.0% |
| EPS (diluted) | $12.82 | $13.89 | $-2.08 | $15.32 | +6.1% |
| EBITDA | $4.44B | $4.61B | $486.3M | $4.87B | +3.1% |
| R&D | $2.66B | $3.69B | $8.26B | $4.04B | +15.0% |
| SG&A | $944.7M | $1.14B | $1.46B | $1.75B | +22.9% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 12,001,300,000 |
|---|---|
| Cost of revenue | 1,651,300,000 |
| Gross profit | 10,350,000,000 |
| Operating expenses | 5,795,600,000 |
| Operating income | 4,554,400,000 |
| Non-operating items and tax | -601,200,000 |
| Net income | 3,953,200,000 |
| Total assets | 25,643,000,000 |
|---|---|
| Cash | 5,084,800,000 |
| Current assets | 11,201,000,000 |
| Total liabilities | 6,977,200,000 |
| Current liabilities | 3,861,200,000 |
| Shareholders’ equity | 18,665,800,000 |
Point-in-time financial data used in the 2026-05-10 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | 8.9B | 4.4B | 3.3B | 4.1B | 3.9B | 204.7M | 148.3M | 491.3M | 172M | — | -85.5M | — | — | — | — | 10.5B | 899.7M | 47.6% | — | 6.5% | — |
| 2023-12-31 | 9.9B | 4.6B | 3.6B | 3.5B | 3.3B | 258.4M | 181.3M | 581.2M | 653.7M | — | -44.9M | — | — | — | — | 10.4B | 808.4M | 38.3% | — | 6.4% | — |
| 2024-12-31 | 11B | 486.3M | -535.6M | -492.6M | -978M | 485.4M | 207.2M | 698.5M | 1.6B | — | -33.6M | — | — | — | — | 4.6B | 1.7B | -2.1% | — | 6.9% | — |
| 2025-12-31 | 12B | 4.9B | 4B | 3.6B | 3.2B | 437.6M | 209.8M | 685.9M | 2.4B | — | -5.4M | — | — | — | — | 5.1B | 2B | 37.9% | — | 6.7% | — |
VRTX trades at 19.9x forward earnings against a peer median of 13.3x; EV/EBITDA of 20.8x against a peer median of 15.2x; 6 peers.
| MRNA |
| Moderna Inc. |
| -13.1x |
| 9.7x |
| -7.7x |
| -36.6% |
| -131.1% |
| INCY | Incyte Corporation | 10.9x | 3.7x | 10.1x | 30.8% | 25.6% |
| TECH | Bio-Techne Corporation | 23.2x | 6.3x | 20.9x | 5.3% | 25.2% |
| LLY | Eli Lilly and Company | 21.4x | 11.7x | 24.4x | 107.5% | 49.4% |
